One day, the number of patients who get MRSA, pneumonia, and other diseases during their stay in the hospital might be decreased with the development of a “superbug” vaccination that momentarily activates the immune system on a high level.
The problem: In the US, one in every 31 hospital patients is fighting an infection that they acquired while receiving treatment for another type of illness. Around 90,000 Americans die each year as a result of healthcare-associated infections (HAIs), which can lengthen a patient’s stay, raise their hospital expense, or worse.
There are presently no vaccines available to protect individuals from the most prevalent of these “superbugs,” although some HAIs are responsive to traditional infection treatments. Instead, the majority of HAIs are brought on by organisms that have developed resistance to existing antimicrobials.